An interesting new clinical trial at Rutgers University is testing the omega 3 fat alpha-linolenic acid (ALA) as a treatment for early stage Alzheimer’s.
rutgers.eduResearchers Test Nutrition-Based Approach to Protect Brain Health in Older Adults at High Risk for Alzheimer’srutgers.edu
The focus is on ApoE4 carriers.
The rationale for using ALA instead of DHA/EPA is that ApoE4 carriers have a difficult time transporting DHA across the blood brain barrier. This might be why previous Alzheimer’s trials with DHA produced lackluster results. The idea is that ALA gets into the brain more easily in ApoE4’s, where it can then be locally converted into DHA.
ALA is naturally found in plant foods such as flaxseeds, chia seeds, walnuts, soybean oil, and canola oil.
Quoted:
ALA is especially promising because it is converted by the body into docosahexaenoic acid (DHA), a fatty acid that plays a critical role in healthy brain structure and function. While DHA supplements have shown limited cognitive benefits in past studies, individuals with the APOE4 genotype often have low levels of DHA in the brain, possibly because of difficulties transporting it across the blood-brain barrier.
“We are looking for safe, affordable strategies that may help protect the brain earlier, before dementia develops,” said Schnaider Beeri, who is leading the study. “By providing ALA, we hope to boost the brain’s own production of DHA, while also improving the health of the blood vessels that supply the brain. In our previous studies using mice engineered to carry the human APOE4 gene, we saw significant improvements in memory as well as in the structure and function of the blood-brain barrier. This clinical study builds on those findings to test whether ALA can produce similar benefits in people.”
The six-month clinical trial is recruiting adults 60 years of age or older with mild cognitive impairment who carry at least one APOE4 allele. Participants will receive either a daily ALA supplement or a placebo. Researchers will assess changes in global cognition, memory and executive function as well as brain imaging measures of blood-brain barrier integrity and cerebral blood flow. Blood tests will examine biomarkers related to brain vessel health and neurodegeneration.
“This study will allow us to look at cognition, brain imaging, and blood markers together,” said Schnaider Beeri. “That gives us a more complete picture of how ALA might benefit brain aging.”


